Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lasofoxifene - Sermonix Pharmaceuticals

Next Previous
Drug Profile

Lasofoxifene - Sermonix Pharmaceuticals

Alternative Names: AZU-101; CP-336156; CP-336156-CB; Fablyn; HLX-78; Lasofoxifene tartrate; Oporia

Latest Information Update: 23 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Eli Lilly and Company; Pfizer; Quantum Leap Healthcare Collaborative; Sermonix Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Naphthalenes; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor alpha antagonist
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; HER2 negative breast cancer
  • Preregistration Submission Withdrawal Atrophic vaginitis; Postmenopausal osteoporosis
  • No development reported Endometrial cancer; Ovarian cancer
  • Discontinued Hypogonadism

Most Recent Events

  • 30 May 2025 Efficacy and adverse events data from a phase II I-SPY trial in Breast cancer presented by 61st Annual Meeting of the American Society of Clinical Oncology(ASCO-2025)
  • 28 May 2025 No recent reports of development identified for preclinical development in Endometrial-cancer in USA (PO)
  • 11 Apr 2025 Efficacy and adverse events data from a phase II I-SPY trial in Breast cancer released by Sermonix Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top